ClinicalTrials.gg
CompletedNCT07352956Updated Apr 14, 2026

A Clinical Study to Evaluate the Effectiveness of an Test Toothpaste for the Relief of Dentin Hypersensitivity in a Chinese Population

An interventional study of Test toothpaste and Sodium fluoride toothpaste in Dentin Sensitivity, sponsored by HALEON. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by HALEON · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 21 studies in Dentin Sensitivity by HALEON — 3 open to participants now, 3 under way, none of them phase 3. Dentin Sensitivity · HALEON.

Enrollment
11th of 20
177 · median 185
Started
2026
with 3 others
No phase
18 of 21
2 open now
Registered
17th of 21
by date

Among the 21 studies in Dentin Sensitivity by HALEON, this one is the 11th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2026, is one of 18 with no phase, and was the 17th registered.

Dentin Sensitivity

292 studies on the registry are indexed under Dentin Sensitivity; 49 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

3 of the 21 studies in Dentin Sensitivity by HALEON are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 20 Dentin Sensitivity studies recruiting now, 6 (30%) set no upper age limit and 13 (65%) stop at 75 or younger; 2 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Dentin Sensitivity by HALEON, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the clinical efficacy of a 0.454 percent (%) weight/weight (w/w) stannous fluoride (SnF2) toothpaste in reducing dentin hypersensitivity (DH) to an evaporative (air) stimulus and tactile stimulus after 28 and 56 days twice daily brushing.

Read the detailed description

This will be a single center, randomized, controlled, examiner-blind, 2-arm, stratified, parallel design clinical study in healthy male and female participants, aged 18-70, with self-reported and clinically confirmed DH in a Chinese population in a study design as per the Chinese Ministry of Health (MOH) Guidance. Sufficient participants will be screened so that approximately 100 participants (50 per group) will be stratified according to the maximum baseline Schiff sensitivity score of their two 'Test Teeth' and randomized to ensure approximately 90 evaluable participants (45 per group) complete the study.

03

Conditions studied

  • Dentin Sensitivity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated document confirming the participant has been informed of all pertinent aspects of the study and has given their written consent for study participation before any study procedures are performed.
  • Participant is biologically male or female.
  • Participant is 18 to 70 years of age at the time of signing the consent form.
  • Participant is willing and able to comply with the study visit schedule, toothpaste usage instructions, lifestyle restrictions, and other study procedures.
  • Participant is in good general, oral, and mental health, which in the opinion of the investigator or medically qualified designee, no or relevant abnormalities in self-reported medical history, or upon oral examination that would impact their safety or wellbeing, or the outcomes of the study if they were to participate in the study, or affect their ability to understand and follow study requirements.
  • Participant who is willing to receive reminders of appointments and videos reminding them on the brushing instructions.
  • Participant must have a self-reported history of tooth sensitivity lasting more than 6 months but not more than 10 years and experience DH symptoms at least 'once a week' or more frequently.
  • Participant must be in general oral health, with a minimum of 20 natural teeth.

Exclusion criteria

Exclusion Criteria:

  • Participant who is an employee of the study site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the study site otherwise supervised by the investigator; or a sponsor employee directly involved in the conduct of the study or a member of their immediate family.
  • Participant who is participating in, or has participated in, other studies (including nonmedicinal studies) involving product(s) within 8 weeks of Screening (Visit 1) or plans to participate in other studies (including non-medicinal studies) during this study.
  • Participant who is participating in, or has participated in, a study evaluating a tooth desensitizing treatment within 8 weeks of Screening (Visit 1).
  • Participant who is using or has used an oral care product indicated for DH relief within 8 weeks of Screening (Visit 1).
  • Participant who has had a professional desensitizing treatment within 8 weeks of Screening (Visit 1).
  • Participant with known or suspected intolerance or to the study products or any of their stated ingredients (or closely related compounds).
  • Participant who is unwilling or unable to comply with product usage instructions or Lifestyle Considerations as described in the protocol.
  • Participant who habitually rinses with water during toothbrushing (self-reported at Screening (Visit 1), or those observed to rinse with water while brushing during the supervised brushing with the allocated toothpaste at screening (Visit 1) or baseline (Visit 2).
  • Female participant who is pregnant or intending to become pregnant during the study (self-reported) or is breastfeeding.
  • Participant with a recent history (within the last year) of alcohol and/or substance abuse.
  • Participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • Participant taking daily doses of medications or traditional herbal treatments which, in the opinion of the investigator or medically qualified designee, could interfere with their perception of pain.

    1. Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilisers, anti-depressants, mood-altering and anti-inflammatory drugs.
    2. Examples of traditional herbal treatments include clove oil, olive oil or other treatments directly applied to the oral cavity for the treatment of oral health conditions.
  • Participant taking daily doses of a medication which, in the opinion of the investigator or medically qualified designee, may cause xerostomia.
  • Participant who needs antibiotic prophylaxis for dental procedures.
  • Participant who has taken antibiotics within 2 weeks of screening (Visit 1) and Baseline visit (Visit 2) (during the acclimatization period).
  • Participant who has had a professional or self-applied tooth bleaching procedure within 8 weeks of Screening (Visit 1).
  • Participant who has had dental prophylaxis within 4 weeks of Screening (Visit 1).
  • Participant who has had treatment for periodontal disease (including surgery) within 12 months of Screening (Visit 1).
  • Participant who has had scaling or root planning within 3 months of Screening (Visit 1).
  • Participant with a tongue or lip piercing.
  • Participant with, in the opinion of the investigator or medically qualified designee, gross periodontal disease.
  • Participant with evidence of gross intra-oral neglect or the need for extensive dental therapy.
  • Participant with a fixed or removable partial prosthesis which, in the opinion of the investigator or medically qualified designee, would impact study outcomes.
  • Participant with multiple dental implants which, in the opinion of the investigator or medically qualified designee, would impact study outcomes.
  • Participant with fixed or removable orthodontic braces/bands or a fixed orthodontic retainer.
  • Participant who is unable to provide appropriate responses to the VAS training exercise.
  • Specific dentition exclusions for 'Test Teeth':

    1. Tooth with evidence of current or recent caries or reported treatment of decay within 12 months of Screening (Visit 1).
    2. Tooth with exposed dentin but with deep, defective or facial restorations.
    3. Tooth with full crown or veneer.
    4. Tooth adjacent to a bridge abutment or crown which, in the opinion of the investigator or medically qualified designee, would impact study outcomes.
    5. Sensitive tooth with contributing aetiologies other than EAR to exposed dentine.
    6. Sensitive tooth, in the opinion of the investigator or medically qualified designee, not expected to respond to treatment with an anti-sensitivity toothpaste.
  • Participant who had previously been enrolled in this study.
  • Any participant who, in the opinion of the investigator or medically qualified designee, was not expected to participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    Test Toothpaste

    Participants will be instructed to brush the two test teeth first, then the whole mouth (all teeth) for at least 1-timed minute, twice daily (morning and evening) for 8 weeks. After brushing, participants will rinse once with 10 milliliter (ml) water using the measuring cup provided.

    Drug: Test toothpaste

  • Other
    Control Toothpaste

    Participants will be instructed to brush the whole mouth (all teeth) for 1-timed minute, twice daily (morning and evening) for 8 weeks. After brushing, rinse once with 10 ml water using the measuring cup provided.

    Drug: Sodium fluoride toothpaste

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Schiff Sensitivity Score at Day 56

    Evaporative (air) sensitivity will be assessed by participant's response to an evaporative (air) stimulus after stimulation of 2 selected test teeth. Response of participant will be scored using Schiff sensitivity scale which ranges from 0-3, where 0=Does not respond to air stimulation; 1=Responds to air stimulus but does not request discontinuation of stimulus; 2=Responds to air stimulus and requests discontinuation or moves from stimulus; 3=Responds to stimulus, considers stimulus to be painful and requests discontinuation of the stimulus. Schiff sensitivity score= average score of the 2 'test teeth' identified at baseline. Change from baseline= Score at Day 56 minus baseline score. A decrease in Schiff sensitivity score indicates an improvement.

    Time frame: Baseline and Day 56

  2. Change From Baseline in Tactile Threshold (grams [g]) at Day 56

    The tactile sensitivity will be assessed by administrating a constant pressure using a Yeaple probe. The tactile threshold is the maximum pressure applied without the participant reporting pain or discomfort. The tactile threshold for 2 selected test teeth will be determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gives two consecutives 'yes' responses will be recorded as the tactile threshold. The greater the tactile threshold, the less sensitive the tooth. Tactile threshold= average value for the two 'test teeth' identified at baseline. Change from baseline= Score at Day 56 minus baseline score.

    Time frame: Baseline and Day 56

Secondary outcomes

  1. Change From Baseline in Schiff Sensitivity Score at Day 56 (Test versus [vs] Control Toothpaste)

    Evaporative (air) sensitivity will be assessed by participant's response to an evaporative (air) stimulus after stimulation of 2 selected test teeth. Response of participant will be scored using Schiff sensitivity scale which ranges from 0-3, where 0=Does not respond to air stimulation; 1=Responds to air stimulus but does not request discontinuation of stimulus; 2=Responds to air stimulus and requests discontinuation or moves from stimulus; 3=Responds to stimulus, considers stimulus to be painful and requests discontinuation of the stimulus. Schiff sensitivity score= average score of the 2 'test teeth' identified at baseline. Change from baseline= Score at Day 56 minus baseline score. A decrease in Schiff sensitivity score indicates an improvement.

    Time frame: Baseline and Day 56

  2. Change From Baseline in Tactile Threshold (g) at Day 56 (Test vs Control Toothpaste)

    The tactile sensitivity will be assessed by administrating a constant pressure using a Yeaple probe. The tactile threshold is the maximum pressure applied without the participant reporting pain or discomfort. The tactile threshold for 2 selected test teeth will be determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gives two consecutives 'yes' responses will be recorded as the tactile threshold. The greater the tactile threshold, the less sensitive the tooth. Tactile threshold= average value for the two 'test teeth' identified at baseline. Change from baseline= Score at Day 56 minus baseline score.

    Time frame: Baseline and Day 56

  3. Change From Baseline in Schiff Sensitivity Score at Day 28

    Evaporative (air) sensitivity will be assessed by participant's response to an evaporative (air) stimulus after stimulation of 2 selected test teeth. Response of participant will be scored using Schiff sensitivity scale which ranges from 0-3, where 0=Does not respond to air stimulation; 1=Responds to air stimulus but does not request discontinuation of stimulus; 2=Responds to air stimulus and requests discontinuation or moves from stimulus; 3=Responds to stimulus, considers stimulus to be painful and requests discontinuation of the stimulus. Schiff sensitivity score= average score of the 2 'test teeth' identified at baseline. Change from baseline= Score at Day 28 minus baseline score. A decrease in Schiff sensitivity score indicates an improvement.

    Time frame: Baseline and Day 28

  4. Change From Baseline in Tactile Threshold (g) at Day 28

    The tactile sensitivity will be assessed by administrating a constant pressure using a Yeaple probe. The tactile threshold is the maximum pressure applied without the participant reporting pain or discomfort. The tactile threshold for 2 selected test teeth will be determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gives two consecutives 'yes' responses will be recorded as the tactile threshold. The greater the tactile threshold, the less sensitive the tooth. Tactile threshold= average value for the two 'test teeth' identified at baseline. Change from baseline= Score at Day 28 minus baseline score.

    Time frame: Baseline and Day 28

  5. Change From Baseline in (Visual Analogue Scale) VAS Scores at Day 28 and 56

    Evaporative (air) sensitivity will be assessed by participant's response to an evaporative (air) stimulus after stimulation of 2 selected test teeth. Response of participant will be scored using Schiff sensitivity scale which ranges from 0-3, where 0=Does not respond to air stimulation; 1=Responds to air stimulus but does not request discontinuation of stimulus; 2=Responds to air stimulus and requests discontinuation or moves from stimulus; 3=Responds to stimulus, considers stimulus to be painful and requests discontinuation of the stimulus. Participants then rated the intensity of their response to the evaporative (air) stimulus using a 100 millimeter (mm) VAS with scores ranging from 0 mm (No discomfort) to 100 mm (extreme discomfort; worst imaginable). Higher score indicated worse outcome (higher sensitivity). Change from baseline will be calculated by subtracting Baseline value from the value at the indicated timepoints.

    Time frame: Baseline, Day 28 and Day 56

07

Study locations

1 site
  • West China School/Hospital of Stomatology, Sichuan University
    Chengdu, Sichuan 610041, China
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Apr 2026, 2 months.

Of 34 industry-sponsored interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's 2 months is below that.

Counting every sponsor, half of 146 studies reached it within 6 months; a quarter within 3 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 20, 2026
StartActual
Jan 16, 2026
Primary completionActual
Apr 6, 2026
CompletionActual
Apr 6, 2026
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07352956
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Jan 20, 2026
Start date
Jan 16, 2026
Primary completion
Apr 6, 2026
Completion
Apr 6, 2026
Last update
Apr 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion